Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2012
12/05/2012CN102260315B Ursolic acid derivatives with anticancer activity and preparation method thereof
12/05/2012CN102258758B High-content liquid gingerols and preparation method thereof
12/05/2012CN102225209B Preparation method of nano magnetic granule composite system
12/05/2012CN102210672B Application of polyketide in preparation of angiogenesis inhibiting medicine
12/05/2012CN102204942B Method for extracting corylus heterophylla leaf flavone
12/05/2012CN102198080B Adriamycin sustained-release medicinal rod for treating Cerebral gliomas disease and preparation method thereof
12/05/2012CN102178960B Application of Tap73 gene in preparation of cancer stem cell chemosensitization medicine
12/05/2012CN102151260B Andrographolide and berberine combination and application thereof
12/05/2012CN102106851B Application of brusatol as chemotherapeutic drug synergist
12/05/2012CN102085375B In-situ magnetically-heated temperature-sensitive targeted nano drug carrier for reversal of multi-drug resistance in tumors
12/05/2012CN102070599B Norsesquiterpenoid peroxide and preparation method and application thereof
12/05/2012CN102070532B Anti-tumor medicament structure
12/05/2012CN102056609B Pharmaceutical combination
12/05/2012CN102018686B Mitomycin-containing film agent and preparation method thereof
12/05/2012CN101918018B Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
12/05/2012CN101884620B Activated carbon granule of load quantum dots as well as preparation method and application thereof
12/05/2012CN101863901B 2-(substituted phenyl)-2-(4,5,6,7-thiophane[3,2-c] pyridine-5(4H)-group)-N-substitute-acetamide as well as preparation method and application thereof
12/05/2012CN101785767B Application of dehydrogenated silibinin diether in preparation of medicaments for preventing and treating leukemia
12/05/2012CN101756988B Compound matrine and diversine nano-emulsion preparation and preparation method thereof
12/05/2012CN101732340B Application of ophicalcitum extract and method for preparing same
12/05/2012CN101590229B Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
12/05/2012CN101565404B Heterocyclic compounds
12/05/2012CN101415424B Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
12/05/2012CN101415409B Combinations of therapeutic agents for treating cancer
12/05/2012CN101287507B Methods and devices for lymphatic targeting
12/05/2012CN101084204B Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
12/04/2012US8324386 Somatostatin-dopamine chimeric analogs
12/04/2012US8324362 Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptors
12/04/2012US8324284 Migrastatin analogs and uses thereof
12/04/2012US8324282 Alkylating agent combinations in the treatment of cancer
12/04/2012US8324267 Kinase inhibitors and the use thereof
12/04/2012US8324245 Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same
12/04/2012US8324242 Modulators of ATP-binding cassette transporters
12/04/2012US8324240 Fused amino pyridine as HSP90 inhibitors
12/04/2012US8324205 Quinazoline derivatives as kinase inhibitors
12/04/2012US8324202 5-phenyl-1H-benzo [E] [1,4] diazepine compounds substituted with an hydroxamic acid group as histone deacetylase inhibitors
12/04/2012US8324190 Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones
12/04/2012US8324180 Compositions and methods for treating cancer
12/04/2012US8324177 Triterpene compositions and methods for use thereof
12/04/2012US8323906 Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
12/04/2012US8323669 Polymer conjugate of taxane
12/04/2012CA2687265C P70 s6 kinase inhibitors
12/04/2012CA2573479C Effective use method of medicaments and method of preventing expression of side effect
12/04/2012CA2551493C Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
12/04/2012CA2526989C Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
12/04/2012CA2520732C Migrastatin analogs and uses thereof
12/04/2012CA2463879C Glycoprotein compositions
12/04/2012CA2422294C Modulation of il-2- and il-15-mediated t cell responses
12/04/2012CA2400868C Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
12/04/2012CA2349442C Compositions and methods for wt1 specific immunotherapy
12/04/2012CA2222509C Connective tissue growth factor
12/04/2012CA2210484C Composition to ameliorate osteolysis and metastasis
11/2012
11/29/2012WO2012162629A2 Popcorn shape gold nanoparticle for targeted diagnosis, photothermal treatment and in-situ monitoring therapy response for cancer and multiple drug resistance bacteria
11/29/2012WO2012162627A1 Treatment of angiogenic- or vascular-associated diseases
11/29/2012WO2012162584A1 Combination therapy of hsp90 inhibitory compounds with chk inhibitors
11/29/2012WO2012162565A2 Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
11/29/2012WO2012162513A2 Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
11/29/2012WO2012162482A1 Immunoconjugates, compositions containing them, and methods of making and use
11/29/2012WO2012162468A1 Thiazol derivatives as pro -matrix metalloproteinase inhibitors
11/29/2012WO2012162463A1 Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation
11/29/2012WO2012162461A1 Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
11/29/2012WO2012162372A1 Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
11/29/2012WO2012162365A1 Substituted sulfonamides useful as antiapoptotic bcl inhibitors
11/29/2012WO2012162307A2 Crosslinked polymer nano-assemblies and uses thereof
11/29/2012WO2012162257A2 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
11/29/2012WO2012162243A2 Anti-cgrp compositions and use thereof
11/29/2012WO2012162089A2 Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth
11/29/2012WO2012162054A1 Dynamic inhibitors of heat shock protein 90
11/29/2012WO2012161951A1 Peptides for preventing or treating a disease or disorder associated with cbp or p300 misregulation, and methods for use and identification thereof
11/29/2012WO2012161879A1 Thiazole derivatives
11/29/2012WO2012161877A1 Pyridine-and pyrazine derivatives
11/29/2012WO2012161812A1 Tricyclic inhibitors of kinases
11/29/2012WO2012161799A1 Epidithiodioxopiperazines and uses thereof in treating cancer
11/29/2012WO2012161776A1 Solid forms of a pharmaceutically active substance
11/29/2012WO2012161677A1 TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY
11/29/2012WO2012161545A2 Composition for promoting apoptosis or inhibiting cell growth, comprising epstein-barr virus microrna
11/29/2012WO2012161539A2 Sirna for inhibiting the expression of bhrf1 and composition comprising same
11/29/2012WO2012161372A1 Double-target antibody fused with a peptide and use of same
11/29/2012WO2012161352A1 Reic-expressing adenovirus vector
11/29/2012WO2012161240A1 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
11/29/2012WO2012161124A1 Composition containing micro rna or expression system thereof
11/29/2012WO2012160990A1 Igf-1r-binding peptide
11/29/2012WO2012160568A1 Process for preparing docetaxel trihydrate polymorph
11/29/2012WO2012160464A1 Heterocyclic compounds as protein kinase inhibitors
11/29/2012WO2012160447A1 3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases
11/29/2012WO2012160223A1 Pharmaceutical composition
11/29/2012WO2012160218A1 Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars
11/29/2012WO2012160215A1 Soluble protein cd5 or cd6 for the treatment of cancer or tumor or for use as an adjuvant
11/29/2012WO2012160186A1 Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use
11/29/2012WO2012160153A1 Agents for treating tumours
11/29/2012WO2012160030A1 Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
11/29/2012WO2012160029A1 Substituted triazolopyridines
11/29/2012WO2012159959A1 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
11/29/2012WO2012159751A1 Hydrazidomycins
11/29/2012WO2012159565A1 6-(aryl-carboxamide) imidazo [1,2-a] pyrimidine and 6-(aryl carboxamide) [1,2,4] triazolo [4,3-a] pyrimidine as hedgehog pathway inhibitor and use thereof
11/29/2012WO2012159562A1 Truncated human papillomavirus type 33 protein l1
11/29/2012WO2012159557A1 Substituted triazine phenylurea derivative and use thereof against tumors
11/29/2012WO2012159550A1 Fgfr-fc fusion protein and use thereof
11/29/2012WO2012159548A1 Fusion protein for antagonizing angiogenesis inducible factors and uses thereof
11/29/2012WO2012159457A1 Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof
1 ... 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 ... 2211